Implantable drug delivery system improves tolerability of anti-CD40/anti-PD1 and chemotherapy in a murine model of breast cancer
Samantha J. Wade(University of Wollongong), Kara L. Vine(University of Wollongong), Junyun Lai(The University of Melbourne), Ross J. Turner(University of Wollongong), Naila Islam(University of Wollongong), Daniel Brungs(University of Wollongong), Paul A. Beavis(Peter MacCallum Cancer Centre), Gordon G. Wallace(University of Wollongong), Alistair Lochhead(University of Wollongong), Elahe Minaei(University of Wollongong), C. Penney(University of Wollongong), A. Hope(University of Wollongong), Morteza Aghmesheh(New South Wales Department of Health)
Cited by 1
Related Papers
Processable aqueous dispersions of graphene nanosheets
|Nature Nanotechnology|2008|9.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
|Journal of Controlled Release|2018|297
Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
|Anti-Cancer Agents in Medicinal Chemistry|2009|269